Morgan Stanley’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-170,902
Closed -$16.6M – 6904
2019
Q3
$16.6M Buy
170,902
+64,913
+61% +$6.5M ﹤0.01% 1647
2019
Q2
$10.9M Sell
105,989
-124,571
-54% -$13.4M ﹤0.01% 2068
2019
Q1
$26.3M Buy
230,560
+31,694
+16% +$2.33M 0.01% 1252
2018
Q4
$7.78M Buy
198,866
+41,031
+26% +$1.78M ﹤0.01% 2396
2018
Q3
$8.61M Sell
157,835
-304,286
-66% -$20.8M ﹤0.01% 2562
2018
Q2
$38.2M Buy
462,121
+72,744
+19% +$5.61M 0.01% 1073
2018
Q1
$25.9M Buy
389,377
+217,978
+127% +$12.6M 0.01% 1431
2017
Q4
$8.81M Buy
171,399
+108,100
+171% +$7.77M ﹤0.01% 2529
2017
Q3
$5.64M Buy
63,299
+4,378
+7% +$332K ﹤0.01% 2841
2017
Q2
$3.52M Buy
58,921
+659
+1% +$36.8K ﹤0.01% 3257
2017
Q1
$3.11M Sell
58,262
-25,398
-30% -$1.51M ﹤0.01% 3395
2016
Q4
$4.18M Buy
83,660
+35,942
+75% +$1.93M ﹤0.01% 3190
2016
Q3
$2.87M Buy
47,718
+21,203
+80% +$1.22M ﹤0.01% 3194
2016
Q2
$1.36M Sell
26,515
-107,883
-80% -$4.61M ﹤0.01% 3730
2016
Q1
$3.97M Sell
134,398
-21,276
-14% -$671K ﹤0.01% 2743
2015
Q4
$7.05M Sell
155,674
-717
-0.5% -$37.6K ﹤0.01% 2328
2015
Q3
$6.53M Sell
156,391
-9,354
-6% -$488K ﹤0.01% 2401
2015
Q2
$10M Sell
165,745
-45,726
-22% -$3.02M ﹤0.01% 2112
2015
Q1
$16.4M Buy
+211,471
New +$12.2M 0.01% 1620

Morgan Stanley's ONCE Position: Q4 2019 in Review

Morgan Stanley sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 170,902 shares — an estimated $16.6M sold.

Morgan Stanley first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $38.2M in Q2 2018. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • Morgan Stanley reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Morgan Stanley sold 170,902 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $16.6M.
  • Morgan Stanley first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
  • Morgan Stanley's Spark Therapeutics, Inc. Common Stock position peaked at $38.2M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Morgan Stanley's 13F filing for Q4 2019, filed 14 Feb 2020.